Many diseases are driven by the expression of specific RNAs within human and pathogen cells. Current treatment options for these diseases may lack the precision to target the underlying genetic causes or may have significant side effects.

1E Therapeutics is developing a new class of programmable oligonucleotide therapeutics designed to autonomously silence disease-causing RNAs in human and pathogen cells. Their patented platform creates targeted therapies that address chronic and life-threatening indications, as well as emerging and evolving pathogens. This approach offers the potential for safer and more precise treatments for a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions. By directly silencing the RNAs responsible for disease, 1E Therapeutics aims to provide more effective and targeted therapeutic interventions.

Programmable oligonucleotide therapeutics for targeted RNA silencing

Patented platform for creating safer and more targeted therapies

Ability to address a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions

Designed to autonomously and precisely silence disease-causing RNAs in human or pathogen cells

The primary target audience includes patients suffering from genetically driven diseases, chronic conditions, and multidrug-resistant infections, as well as healthcare providers seeking more precise and effective treatment options.